Apogee therapeutics to host conference call to report part a 16-week data from the phase 2 apex trial of apg777 in patients with moderate-to-severe atopic dermatitis on july 7, 2025

San francisco and boston, july 06, 2025 (globe newswire) -- apogee therapeutics, inc., (nasdaq: apge), a clinical-stage biotechnology company advancing novel biologics with the potential for differentiated efficacy and dosing in the largest inflammatory and immunology (i&i) markets, including for the treatment of atopic dermatitis (ad), asthma, eosinophilic esophagitis (eoe), chronic obstructive pulmonary disease (copd) and other i&i indications, today announced it will report part a 16-week data from the phase 2 apex trial of apg777 on monday, july 7, 2025. following the announcement, the company will host a conference call and webcast at 8:00 a.m.
APG Ratings Summary
APG Quant Ranking